跳至主要内容
临床试验/JPRN-jRCT2080223763
JPRN-jRCT2080223763已完成3 期

Open label study of FSN-011-01 in Japanese women with menopausal disorder with uterus

Fuji Pharma, Co, Ltd0 个研究点目标入组 350 人开始时间: 2017年12月25日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
350

研究概览

简要总结

After co-administration of FSN-011-01 with estrogen preparation for 52 weeks, no endometrial hypertrophy was observed. It was confirmed that the upper boundary of the two-sided 95% confidence interval for the incidence was below the predetermined level of 2.0%. Regarding safety, the majority of subjects completed the trial, so there were no major tolerability concerns.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 45age old 至 <= 64age old(—)
性别
Female

入选标准

  • Japanese menopausal women with uterus to undergo hormone replacement therapy

排除标准

  • -Subjects who are positive or indeterminable with 5 mm or more of endometrial thickness in endometrial biopsy
  • -Subjects who are not able to undergo endometrial biopsy procedurally due to cervical stenosis, etc. at screening (Visit 1).
  • -Subjects who have serious liver injury at screening (Visit 1)
  • -Subjects who have or are suspected to have malignant tumor at screening (Visit 1)
  • -Subjects who have past medical history of breast cancer

研究者

相似试验